CA
CNTA

Crewe Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Crewe Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-220
Closed -$847 – 900
2023
Q1 		$847 Hold
220
– – ﹤0.01% 765
2022
Q4 		$682 Hold
220
– – ﹤0.01% 955
2022
Q3 		$1K Hold
220
– – ﹤0.01% 1124
2022
Q2 		$1K Buy
+220
New +$1.41K ﹤0.01% 1048

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Crewe Advisors's CNTA Position: Q2 2023 in Review

Crewe Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2023, closing a stake of 220 shares — an estimated $847 sold.

Crewe Advisors first reported a position in CNTA in Q2 2022 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 45 funds tracked by Wall St. Rank hold CNTA as of Q2 2023.

  • Crewe Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 220 Centessa Pharmaceuticals shares in Q2 2023, an estimated $847.
  • Crewe Advisors first reported a position in Centessa Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Centessa Pharmaceuticals position peaked at $1K in Q3 2022.
  • 45 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.